Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2023 | Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer | Denkert, Carsten; Lambertini, Chiara; Fasching, Peter A; Pogue-Geile, Katherine L; Mano, Max S; Untch, Michael; Wolmark, Norman; CHIUN-SHENG HUANG ; et al., | Clinical cancer research : an official journal of the American Association for Cancer Research | 10 | 5 | |
2021 | Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis | Gelmon, Karen A; Fasching, Peter A; Couch, Fergus J; Balmaña, Judith; Delaloge, Suzette; Labidi-Galy, Intidhar; Bennett, James; CHIUN-SHENG HUANG ; et al. | European journal of cancer (Oxford, England : 1990) | 19 | 19 | |
2023 | Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer | Slamon, Dennis J; Fasching, Peter A; Hurvitz, Sara; Chia, Stephen; Crown, John; Martín, Miguel; Barrios, Carlos H; Bardia, Aditya; Im, Seock-Ah; Yardley, Denise A; Untch, Michael; CHIUN-SHENG HUANG ; et al., | Therapeutic advances in medical oncology | 20 | 5 | |